Venetoclax/Rituximab Combo Approved in Europe for CLL

November 1, 2018 – The European Commission has approved venetoclax for use in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) following at least 1 prior therapy. The approval was based on findings from the phase III MURANO trial, results of which were published in the New England Journal of Medicine. After a median follow-up of 23.8 months, the progression-free survival (PFS) rate … (leggi tutto)